Premature MicroRNA-Based Therapeutic: A “One-Two Punch” against Cancers
Department of Neurosurgery, Zhongshan Hospital Xiamen University, Xiamen 361004, China
Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, China
Laboratory of Neuro-Oncology, Key Laboratory of Neurotrauma, Variation, and Regeneration, Ministry of Education and Tianjin Municipal Government, Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, China
Authors to whom correspondence should be addressed.
Received: 2 November 2020 / Revised: 12 December 2020 / Accepted: 16 December 2020 / Published: 18 December 2020
The current understanding of miRNA biology is greatly derived from studies on the guide strands and the passenger strands, also called miRNAs*, which are considered as carriers with no sense for long periods. As such, various studies alter the expression of guide strands by manipulating the expression of their primary transcripts or precursors, both of which are premature miRNAs. In this situation, the regulatory miRNA* species may interfere with the phenotypic interpretation against the target miRNA. However, such methods could manipulate the expression of two functionally synergistic miRNAs of the same precursor, leading to therapeutic potential against various diseases, including cancers. Premature miRNAs represent an underappreciated target reservoir and provide molecular targets for “one-two punch” against cancers. Examples of targetable miRNA precursors and available targeting strategies are provided in this review.